Researchers suspected cytochrome P450 monooxygenases and the fatty acid metabolites known as epoxyoctadecenoic acids, increased colon cancer tumor production.
Researchers performed metabolomics on healthy mice and mice with colon cancer finding that the plasma and colon concentrations of epoxyoctadecenoic acids were dramatically increased and CYP monooxygenases were overexpressed.
Researchers then studied human colon cancer cells, finding CYP monooxygenases were also overexpressed. They believe medication targeting the CYP monooxygenase pathway could be developed to either prevent or treat colon cancer.
Study author Guodong Zhang, PhD, said, “We think this is a very interesting discovery. Our research identifies a novel therapeutic target and could help to develop novel strategies to reduce the risks of colon cancer.”
The findings were published in Cancer Research.
More articles on gastroenterology:
After ending partnership, West Cancer Center acquires Methodist Le Bonheur campus with surgery center — 6 insights
UCHealth Yampa Valley Medical Center, Steamboat Orthopaedic & Spine Institute to develop ASC: 4 highlights
5 revenue cycle metrics & factors for ASCs to monitor
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
